357 related articles for article (PubMed ID: 17338793)
1. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations.
Tuettenberg A; Schmitt E; Knop J; Jonuleit H
J Dtsch Dermatol Ges; 2007 Mar; 5(3):190-6. PubMed ID: 17338793
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
4. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
5. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
[TBL] [Abstract][Full Text] [Related]
6. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination.
Correll A; Tuettenberg A; Becker C; Jonuleit H
Exp Dermatol; 2010 Aug; 19(8):e213-21. PubMed ID: 20500773
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells for specific cancer immunotherapy.
Meidenbauer N; Andreesen R; Mackensen A
Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell vaccination as a treatment modality for melanoma.
Eubel J; Enk AH
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
[TBL] [Abstract][Full Text] [Related]
9. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
10. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
Verdijk P; Aarntzen EH; Lesterhuis WJ; Boullart AC; Kok E; van Rossum MM; Strijk S; Eijckeler F; Bonenkamp JJ; Jacobs JF; Blokx W; Vankrieken JH; Joosten I; Boerman OC; Oyen WJ; Adema G; Punt CJ; Figdor CG; de Vries IJ
Clin Cancer Res; 2009 Apr; 15(7):2531-40. PubMed ID: 19318472
[TBL] [Abstract][Full Text] [Related]
11. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
[TBL] [Abstract][Full Text] [Related]
12. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789
[TBL] [Abstract][Full Text] [Related]
13. [New aspects of immunotherapy of malignant melanoma].
Enk A
Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
[TBL] [Abstract][Full Text] [Related]
14. Skin biopsies in DC vaccines for stage III-IV melanoma patients: role of neutrophils?
Laporte M; Trakatelli M; Vereecken P; Blocklet D; Lespagnard M; Petein M; Goldman M; Velu T; Heenen M
Arch Dermatol Res; 2007 Dec; 299(10):483-6. PubMed ID: 17934742
[TBL] [Abstract][Full Text] [Related]
15. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
16. [Advances in cellular immunotherapy for malignant melanoma].
López M; Escobar A; Alfaro J; Fodor M; Larrondo M; Ferrada C; Salazar-Onfray F
Rev Med Chil; 2004 Sep; 132(9):1115-26. PubMed ID: 15543770
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
18. Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency.
Yoshikawa T; Niwa T; Mizuguchi H; Okada N; Nakagawa S
Gene Ther; 2008 Oct; 15(19):1321-9. PubMed ID: 18480845
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell vaccination for cancer therapy.
Nestle FO
Oncogene; 2000 Dec; 19(56):6673-9. PubMed ID: 11426654
[TBL] [Abstract][Full Text] [Related]
20. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
